Change in FeNO with dupilumab and tezepelumab in severe eosinophilic asthma

被引：0
|
作者：
Gates, J. [1 ]
Hearn, A. [1 ]
Maynard-Paquette, A. C. [1 ]
Green, L. [1 ]
Thomson, L. [1 ]
Fernandes, M. [1 ]
Roxas, C. [1 ]
Lam, J. [1 ]
d'Ancona, G. [1 ]
Dhariwal, J. [1 ]
Nanzer, A. M. [1 ]
Jackson, D. J. [1 ]
机构：
[1] Guys & St Thomas NHS Trust, Guys Severe Asthma Ctr, London, England
来源：
THORAX | 2023年 / 78卷 / SUPPL_4期
关键词：
D O I：
10.1136/thorax-2023-BTSabstracts.411
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
M22
引用
收藏
页码：A274 / A274
页数：1
相关论文
共 50 条
  • [21] Eosinophilic vasculitis associated with persistent dupilumab-induced hypereosinophilia in severe asthma
    Descamps, V.
    Deschamps, L.
    El Khalifa, J.
    Groh, M.
    Gibiere, J. -B.
    Lefevre, G.
    Taille, C.
    RESPIRATORY MEDICINE AND RESEARCH, 2021, 79
  • [22] The effectiveness and value of tezepelumab for severe asthma
    Rind, David M.
    McQueen, R. Brett
    Herron-Smith, Serina
    Herce-Hagiwara, Belen
    Gutierrez, Eric
    Campbell, Jon D.
    Fluetsch, Noemi
    Pearson, Steven D.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (05): : 577 - 580
  • [23] Effect of tezepelumab in patients with severe, uncontrolled asthma by age of onset, allergic status, and eosinophilic phenotype
    Mathur, S. K.
    Hill, J. L.
    Ambrose, C. S.
    Martin, N.
    Llanos, J-P
    Martin, N.
    Colice, G.
    THORAX, 2023, 78 (SUPPL_4) : A86 - A86
  • [24] Tezepelumab in the Treatment of Uncontrolled Severe Asthma
    Feist, Jacqueline
    Lipari, Melissa
    Kale-Pradhan, Pramodini
    ANNALS OF PHARMACOTHERAPY, 2023, 57 (01) : 62 - 70
  • [25] Biomarkers of severe eosinophilic asthma: The role of induced sputum eosinophils, FeNO and blood eosinophils
    Vyff, B. H.
    Skjold, T.
    Hoffmann, H. J.
    Schmid, J. M.
    ALLERGY, 2019, 74 : 385 - 385
  • [26] Exacerbation of Eosinophilic Granulomatosis With Polyangiitis After Administering Dupilumab for Severe Asthma and Eosinophilic Rhinosinusitis With Nasal Polyposis
    Tanaka, Shunya
    Tsuji, Taisuke
    Shiotsu, Shinsuke
    Yuba, Tatsuya
    Hiraoka, Noriya
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (05)
  • [27] TEZEPELUMAB REDUCES ALL KEY INFLAMMATORY BIOMARKER LEVELS IN PATIENTS WITH SEVERE ALLERGIC AND EOSINOPHILIC ASTHMA
    Mathur, S.
    Jacobs, J.
    Ponnarambil, S.
    Martin, N.
    Llanos-Ackert, J.
    Ambrose, C.
    Carr, T.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S43 - S43
  • [28] BASELINE EXHALED NITRIC OXIDE (FENO) AS PREDICTOR OF RESPONSE TO DUPILUMAB IN UNCONTROLLED, MODERATE-TO-SEVERE ASTHMA
    Pavord, I.
    Busse, W.
    Corren, J.
    Casale, T.
    FitzGerald, M.
    Daizadeh, N.
    Ortiz, B.
    Johnson, R.
    Harel, S.
    Rowe, P.
    Deniz, Y.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 125 (05) : S34 - S34
  • [29] Adverse Effects Under Th2 Biologics (Dupilumab and Tezepelumab) in a Patient with Severe Asthma and Atopic Dermatitis
    Suhling, Hendrik
    Hinze, Christopher Alexander
    Welte, Tobias
    Werfel, Thomas
    Traidl, Stephan
    RESPIRATION, 2023, 102 (12) : 1016 - 1019
  • [30] Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
    Menzies-Gow, Andrew
    Corren, Jonathan
    Bourdin, Arnaud
    Chupp, Geoffrey
    Israel, Elliot
    Wechsler, Michael E.
    Brightling, Christopher E.
    Griffiths, Janet M.
    Hellqvist, Asa
    Bowen, Karin
    Kaur, Primal
    Almqvist, Gun
    Ponnarambil, Sandhia
    Colice, Gene
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (19): : 1800 - 1809
12345